PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7581221

Bromocriptine and lactation suppression: are the risks acceptable?

L de Jong-van den Berg·B Mintzes
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

BromocriptineDopamine AgonistsFemaleHumansLactationRisk FactorsUnited StatesEditorial

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L de Jong-van den Berg, B Mintzes. 1995-07-28. Bromocriptine and lactation suppression: are the risks acceptable?. https://doi.org/10.1007/bf01872384

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron.

Membrane lipid peroxidation has been suggested to participate in the nigral degeneration of Parkinson's disease. In the present study, we demonstrate that bromocriptine inhibits lipid peroxidation in phospholipid liposomes induced by dopa and iron complexes. Because this lipid peroxidation is not mediated by active oxygen species, antioxidant properties of bromocriptine do not seem to be derived from radical scavenging effects in our experimental conditions. Bromocriptine had no scavenging effect on superoxide produced by hypoxanthine-xanthine oxidase when determined by the chemiluminescence assay using MCLA, a Cypridina luciferin analog, as a probe.

Bromocriptine↗